Moleculin enters Phase 2 clinical trials, reports bigger net loss in 2022 year-end results
Moleculin is pushing its chemotherapy drug Annamycin into a second phase of clinical trials, with officials confident its data can lead to FDA approval.
Building "Bridges" Across the Bayou City!
Moleculin is pushing its chemotherapy drug Annamycin into a second phase of clinical trials, with officials confident its data can lead to FDA approval.